clinical trial · NCT06088004
Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.·phase2·recruiting·n = 218
Solid Tumor, AdultABO2011 InjectionToripalimab
brief summary
This is an open-label, single-arm, dose-escalation, and dose-expansion clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ABO2011 monotherapy or in combination with Toripalimab in patients with advanced solid tumors.
started
Sep 28, 2023
primary completion
Dec 30, 2026
completion
Dec 30, 2027
last updated
Sep 23, 2026
official title
A Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics (PK/PD) and Preliminary Efficacy of ABO2011 Monotherapy or in Combination With Toripalimab in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol